Amgen To Invest $550 M in New Biomanufacturing PlantBy
Amgen has announced plans to invest $550 million to build a new multi-product biologic drug-substance manufacturing facility in Holly Springs, North Carolina.
The new plant will support traditional stainless-steel-fed batch manufacturing and single-use technologies. Construction of the new plant is expected to begin in December 2021, with an estimated completion date of late 2024. Amgen has committed to a total investment of $550 million, and the establishment of the plant will bring up to 355 full-time jobs to the region by 2029, including engineers, technicians, quality, management and administrative roles.
One of Amgen’s goals for all of its operations is to be carbon neutral by 2027. The new plant is expected to reduce water use by 40% and waste disposal by 75%, compared with a traditional drug-substance manufacturing plant, according to information from the company.
This is a second recent announcement to add further manufacturing capacity in the US. Last month (July 2021), Amgen announced plans to invest $365 million to build a new final product advanced assembly and packaging plant near Columbus, Ohio.